# Secukinumab in refractory non-infectious anterior uveitis

## TL;DR

This study examines the effectiveness of secukinumab in treating non-infectious anterior uveitis but finds it does not prevent flare-ups in patients resistant to other therapies.

## Contribution

The study provides new insights into the limited efficacy of secukinumab for anterior uveitis in patients unresponsive to prior biological therapies.

## Key findings

- All five patients experienced uveitis flare-ups during secukinumab treatment.
- Two patients failed to achieve long-term remission and had uncontrolled systemic disease.
- Secukinumab did not prevent flare-ups in patients with refractory anterior uveitis.

## Abstract

Secukinumab is a monoclonal antibody that selectively neutralizes interleukin-17A and has shown efficacy in the treatment of psoriatic arthritis, psoriasis, and axial spondyloarthritis. Its use in non-anterior non-infectious uveitis is controversial, with evidence generally not supporting its effectiveness in these conditions. However, the role of secukinumab in anterior non-infectious uveitis remains unclear.

Case series. Five patients with biological therapy-refractory non-infectious anterior uveitis who were treated with secukinumab were included.

All 5 patients experienced a uveitis flare-up during treatment, and secukinumab failed to induce long-term remission in 2 of these patients, who also had uncontrolled systemic disease.

Secukinumab failed to prevent uveitis flare-up in these patients with biological therapy-refractory disease. Further studies are necessary to determine the potential role of secukinumab in the treatment of anterior uveitis.